AQST Share Price Performance
US$4.17
1.90 (83.70%)
59.5% undervalued intrinsic discount
US$10.30
Fair Value
Price US$4.17
AnalystConsensusTarget US$10.30
AnalystLowTarget US$6.15
AnalystHighTarget US$11.00
Fair ValueUS$10.30
Share Pricen/a
Aquestive Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
AQST Community Narratives
AN
Fair Value
·Fair Value US$10.3 59.5% undervalued intrinsic discount
Patent Extensions and FDA Momentum Will Support Upcoming Needle-Free Epinephrine Launch
0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
AN
Fair Value
·Fair Value US$6.15 32.2% undervalued intrinsic discount
Reimbursement Barriers And Competition Will Curtail Adoption Yet Potential Appears
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$11 62.1% undervalued intrinsic discount
Patient Centric Needle-Free Therapies Will Capture Global Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Reimbursement Barriers And Competition Will Curtail Adoption Yet Potential Appears
Key Takeaways Barriers like access restrictions, payer dynamics, and education needs may limit rapid revenue growth despite the promise of innovative oral drug delivery products. Dependence on a few high-risk assets and heavy financing requirements expose the company to market share, profitability, and shareholder value risks.Read more
AN
US$6.15
32.2% undervalued intrinsic discount
Fair Value
Profit Margin
19.19%
Future PE
57.78x
Price in 2029
US$7.5
Patient Centric Needle-Free Therapies Will Capture Global Markets
Key Takeaways Accelerated global expansion and unique patient-first strategies could drive faster uptake and broader revenue diversification for Anaphylm than analysts currently anticipate. Oral film technology and scalable PharmFilm portfolio position the company for sustained leadership, margin expansion, and strong long-term earnings leverage as care models evolve.Read more
AN
US$11
62.1% undervalued intrinsic discount
Fair Value
Profit Margin
11.42%
Future PE
114.78x
Price in 2029
US$13.42
Patent Extensions and FDA Momentum Will Support Upcoming Needle-Free Epinephrine Launch
Key Takeaways The FDA review and potential success of Anaphylm could drive strong revenue growth and shift market preference toward needle-free drug delivery. Strategic investments in awareness, payer access, and product pipeline position the company for rapid adoption, diversified revenue, and improved margins.Read more
AN
US$10.3
59.5% undervalued intrinsic discount
Fair Value
Profit Margin
5.45%
Future PE
216.94x
Price in 2028
US$12.56
Trending Discussion
Recently Updated Narratives
AN
AQST: FDA CRL Resolution And 2026 Resubmission Will Drive Long Term Upside
Fair Value: US$6.15 32.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AQST: Regulatory Delay And 2026 Resubmission Will Ultimately Catalyze Allergy Treatment Upside
Fair Value: US$11 62.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AQST: Extended Patent Protection Will Support Future Share Price Outperformance
Fair Value: US$10.3 59.5% undervalued intrinsic discount
14 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Aquestive Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.55
- 63.45%
- -137.08%
- -113.5%
About AQST
- Founded
- 2004
- Employees
- 147
- CEO
- WebsiteView website
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
